BIOGEN (DENMARK) A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  2.1% 2.1% 4.7% 1.2% 1.1%  
Credit score (0-100)  68 67 44 83 82  
Credit rating  BBB BBB BB BBB BBB  
Credit limit (mDKK)  0.0 0.0 0.0 5.7 8.5  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  325 303 260 308 260  
Gross profit  325 303 260 47.0 44.2  
EBITDA  2.0 4.8 -6.8 11.6 9.2  
EBIT  2.0 4.8 -6.8 11.6 9.2  
Pre-tax profit (PTP)  12.3 10.1 7.6 10.9 10.7  
Net earnings  12.3 10.1 7.6 8.4 8.3  
Pre-tax profit without non-rec. items  2.0 4.8 -6.8 10.9 10.7  

 
See the entire income statement

Balance sheet (mDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.2 0.2  
Shareholders equity total  104 114 122 130 139  
Interest-bearing liabilities  0.0 0.0 0.0 6.7 20.5  
Balance sheet total (assets)  211 177 243 160 199  

Net Debt  0.0 0.0 0.0 -88.9 -65.8  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  325 303 260 308 260  
Net sales growth  -8.5% -6.6% -14.4% 18.4% -15.6%  
Gross profit  325 303 260 47.0 44.2  
Gross profit growth  508.2% -6.6% -14.4% -81.9% -6.0%  
Employees  22 24 24 22 20  
Employee growth %  -12.0% 9.1% 0.0% -8.3% -9.1%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  211 177 243 160 199  
Balance sheet change%  6.0% -15.8% 37.2% -34.1% 23.8%  
Added value  2.0 4.8 -6.8 11.6 9.2  
Added value %  0.6% 1.6% -2.6% 3.8% 3.5%  
Investments  -0 0 0 0 0  

Net sales trend  -1.0 -2.0 -3.0 1.0 -1.0  
EBIT trend  4.0 5.0 -1.0 1.0 2.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.6% 1.6% -2.6% 3.8% 3.5%  
EBIT %  0.6% 1.6% -2.6% 3.8% 3.5%  
EBIT to gross profit (%)  0.6% 1.6% -2.6% 24.8% 20.8%  
Net Earnings %  3.8% 3.3% 2.9% 2.7% 3.2%  
Profit before depreciation and extraordinary items %  3.8% 3.3% 2.9% 2.7% 3.2%  
Pre tax profit less extraordinaries %  0.6% 1.6% -2.6% 3.5% 4.1%  
ROA %  1.0% 2.5% -3.2% 5.8% 6.0%  
ROI %  1.3% 2.5% -3.2% 6.1% 7.3%  
ROE %  12.5% 9.3% 6.4% 6.7% 6.2%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  100.0% 100.0% 100.0% 81.4% 69.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 9.7% 23.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% -21.4% -10.3%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% -763.8% -715.9%  
Gearing %  0.0% 0.0% 0.0% 5.2% 14.8%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 22.3% 0.2%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 5.4 3.3  
Current Ratio  0.0 0.0 0.0 5.4 3.3  
Cash and cash equivalent  0.0 0.0 0.0 95.7 86.3  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 65.6 155.9  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 51.7% 76.2%  
Net working capital  0.0 0.0 0.0 129.5 138.5  
Net working capital %  0.0% 0.0% 0.0% 42.1% 53.4%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  15 13 11 14 13  
Added value / employee  0 0 -0 1 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -0 1 0  
EBIT / employee  0 0 -0 1 0  
Net earnings / employee  1 0 0 0 0